Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2012 Financial Results
Date:5/3/2012

orate Overview." 

Forward-Looking Statements Statements included in this press release and Cadence's conference call that are not a description of historical facts are forward-looking statements. Words such as "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements, and are based on Cadence's current beliefs and expectations. Such statements include, without limitation, statements regarding: Cadence's financial guidance, expectations regarding sales and revenue growth and the market opportunity for OFIRMEV; the status of the recall of a single lot of OFIRMEV; the status of Cadence's ongoing investigation into certain quality issues; and Cadence's ability to execute its strategies for acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Cadence's actual future results may differ materially from Cadence's current expectations due to the risks and uncertainties inherent in its business. These risks include, but are not limited to: Cadence's dependence on the successful commercialization of OFIRMEV, which is Cadence's only product; Cadence's ability to achieve broad market acceptance and generate revenues from sales of OFIRMEV; Cadence's dependence on its contract manufacturers and its ability to ensure an adequate and continued supply of OFIRMEV to meet market demand; Cadence's ability to successfully enforce its marketing exclusivities and intellectual property rights, and to defend the patents covering OFIRMEV, including in current patent litigation with the parties that have submitted abbreviated new drug applications ("ANDAs") for generic versions of OFIRMEV; the potential that Cadence may be required to continue patent litigation for substantial lengths of time or file additional l
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston on March 7, 2012
2. Cadence Pharmaceuticals Announces Voluntary Recall of One Lot of OFIRMEV® (Acetaminophen) Injection
3. HealthTech Capital Leads Series A2 With Over $300,000 Investment in Cadence Biomedical
4. Cadence Pharmaceuticals Announces Completion of Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option by Underwriters
5. Cadence Pharmaceuticals Announces Pricing of Public Offering of Common Stock
6. Cadence Pharmaceuticals Reports Third Quarter 2011 Financial Results
7. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2011 Financial Results on November 3, 2011
8. Cadence Pharmaceuticals to Present at Three Investment Conferences During the Month of September 2011
9. Cadence Pharmaceuticals Reports Second Quarter 2011 Financial Results
10. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of August 2011
11. Cadence Pharmaceuticals Reaffirms FDA-Approved Dosing Recommendations for OFIRMEV® (acetaminophen) Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 19, 2014 According to Kalorama Information, electronic ... make Big Data in healthcare a reality, and this ... of the American Recovery and Reinvestment Act, the U.S. ... projects and penalties will start applying soon for use ... its complete study of the EMR industry, EMR ...
(Date:8/19/2014)... , Aug. 19, 2014  Regeneron Pharmaceuticals, Inc. (NASDAQ: ... conferences: , Sanofi and Regeneron will host an IR ... on Tuesday, September 2, 2014 , Baird 2014 ... September 3, 2014 , Citi,s 9 th ... Thursday, September 4, 2014 , Morgan Stanley Global ...
(Date:8/19/2014)... PARK, Calif. , Aug. 19, 2014   DelMar ... a protocol amendment to allow for expanded dosing in its ... and Drug Administration (FDA) and that a new cohort of ... clinical trial sites in the United States ... million have been raised through warrant exercise in two separate ...
Breaking Medicine Technology:Kalorama: EMR Paves the Way for Big Data 2Kalorama: EMR Paves the Way for Big Data 3DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 2DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 3DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 4DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 5DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 6DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 7
... YORK, Nov. 17 Romeo and Juliette Laser ... hair removal center in New York City to own the ... leading developer and manufacturer of laser and light-based aesthetic treatment ... patented MultiPlex sequencing technology, is a highly versatile laser aesthetic ...
... , NEW YORK, Nov. 17 Engineer/pilot/attorney ... credit. They include technology that thwarts piracy in ... behind, devices to enhance airport security and even an ... interests that they have, indeed, found their match. ...
Cached Medicine Technology:Romeo and Juliette Laser Hair Removal Is First Center in New York City to Own Cynosure's New Elite MPX(TM) Laser System 2When Viruses (Including H1N1) and Bacteria are as Close as your Fingertips; VirWall's New Innovation Can Disarm Killer Keyboards 2
(Date:8/19/2014)... (PRWEB) August 20, 2014 Recently, iFitDress.com,a ... occasion outfits, has unveiled its new collection of ... made to expand the company’s global market. Each item ... to the company’s senior spokesman, customers that have specific ... at iFitDress.com. Now, all the brand new items are ...
(Date:8/19/2014)... Aug. 19, 2014 (HealthDay News) -- Lupus and ... as headaches and seizures, which can delay a ... Treatments for rheumatic diseases can also cause ... Loyola University Medical Center in Maywood, Ill. ... the joints and soft tissues, such as lupus, ...
(Date:8/19/2014)... Just back from Glasgow where he helped distribute thousands ... Commonwealth Games (July 23 – August 6), Pete Dwan is ... And the need for his work cannot be overstated. , ... 59 consumed Class A drugs within the last year. And ... (NPS) drugs considered to be “legal highs” until June 2014, ...
(Date:8/19/2014)... Warfarin, the longtime standard treatment for atrial fibrillation, ... anticoagulant drug marketplace including dabigatran, rivaroxaban, and apixaban. ... these novel oral anticoagulants (NOACs) into clinical practice. ... new anticoagulant prescriptions yet this represents 98% of ... The American Journal of Medicine . , ...
(Date:8/19/2014)... City, Utah (PRWEB) August 19, 2014 ... Benefits Solution, published a new guide on compliance ... Zane Benefits, small businesses want to offer employee ... health insurance is unsustainable. Additionally, there are new ... portability, guaranteed-issue, and lower costs. , The ...
Breaking Medicine News(10 mins):Health News:Discounted Pewter Evening Dresses For 2014 Unveiled By Company iFitDress.com 2Health News:Certain Symptoms Can Delay Lupus Diagnosis, Researchers Report 2Health News:British Scientologist on a Mission to Save Youth from Drug Abuse 2Health News:Novel oral anticoagulant prescriptions soar, but at a high cost 2Health News:Novel oral anticoagulant prescriptions soar, but at a high cost 3
... medications is associated with increased severity of erectile dysfunction, according ... British Journal of Urology International ., This study surveyed 37,712 ... taking various medications are likely to have more severe ED. ... multiethnic cohort of men ages 46 to 69 who are ...
... NJ . November 13, 2011. Kessler Foundation received a ... Geriatric Life Improvement. Anna Barrett, MD, director of Stroke ... to finding better ways to treat hidden disabilities that ... are pleased to receive this grant," said Rodger DeRose, ...
... By Serena Gordon HealthDay Reporter , MONDAY, Nov. ... warfarin need blood tests every four weeks to make sure ... suggests that some people could safely have those tests done ... isn,t an option for everyone on warfarin, just those who ...
... News) -- Drinking alcohol may be especially risky for young ... including having mothers, grandmothers or aunts with the disease, a ... Medicine in St. Louis examined data on more than 9,000 ... aged 9 to 15) through 2007. They focused on ...
... Indianapolis Wishard Health Services chief medical information officer, ... named one of America,s leading clinical informaticists by Modern ... Dr. Dexter is an associate professor of clinical medicine ... director of clinical applications at Wishard. "Dr. ...
... MONDAY, Nov. 14 (HealthDay News) -- Hearing loss affects ... far higher number than previously believed, researchers report. ... during National Health and Nutritional Examination Surveys (NHANES) from ... Organization,s definition of hearing loss (unable to hear sounds ...
Cached Medicine News:Health News:Erectile dysfunction increases with use of multiple medications 2Health News:Erectile dysfunction increases with use of multiple medications 3Health News:Kessler Foundation awarded stroke research grant by Wallerstein Foundation 2Health News:Warfarin May Need Less Monitoring for Some 2Health News:Warfarin May Need Less Monitoring for Some 3Health News:Drinking Risky for Women With Family History of Breast Cancer: Study 2Health News:Drinking Risky for Women With Family History of Breast Cancer: Study 3Health News:Indianapolis doc recognized as one of nation's top health info tech experts 2Health News:Indianapolis doc recognized as one of nation's top health info tech experts 3Health News:Hearing Loss Far More Common Than Expected 2
The ACMI TurboFlow 18 L and 10 L Insufflators provide rapid distention for all laparoscopic procedures. Eleven built-in safety features make insufflation reliable and dependable....
This multiple-function instrument allows the surgeon to grasp, coagulate, and transect tissue with a single instrument, eliminating the need for multiple instruments and, in some procedures, costly l...
Bipolar forceps...
... An in vitro Nucleic Acid ... using Microplate Chemiluminescence for the ... (HPV) Types 6,11,16,18,31,33,35,39,42,43,44,45,51,52,56,58,59 and 68 ... Lowand High-Risk Groups in Cervical ...
Medicine Products: